In the News

For the third year, the Society of Nuclear Medicine and Molecular Imaging's Patient Advocacy Advisory Board developed a Patient Program to address key topics of interest to the patient and patient advocacy community.  These presentations were given at the SNMMI Patient Education Day, June 9th in Vancouver, BC.

BREAKING NEWS â€“ the radiopharmaceutical Gallium-68 (DOTA0-hel-Tyr3) octreotide (Ga-68 DOTATOC) has been designated as an orphan drug by the US Food and Drug Administration (FDA) for the management of neuroendocrine tumors. This designation is significant because it may lead to faster approval of the agent, which would greatly benefit carcinoid/NET patients in the United States. Click here to read the full release the Society of Nuclear Medicine and Molecular Imaging and from

A committee of international experts under the auspices of the International Atomic Energy Agency (IAEA), in cooperation with the EANM Therapy, Oncology and Dosimetry Committees and with the Society of Nuclear Medicine and Molecular Imaging, worked together to create this guidance document on the use of somatostatin analogue-based PRRNT. This 120 page guidance document released in February 2013, was compiled taking into account recent literature and experts’ opinion and can be downloaded here